What is PSNL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.71B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PSNL?

P/E (TTM) is n/a and 52-week range is $4.96 to $18.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PSNL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PSNL?

The company profile lists revenue (TTM) near $71M, net income (TTM) near $-10.85B, EPS (TTM) near $-1.09 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Personalis Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Fremont, California, US, 106.8M shares outstanding, ISIN US71535D1063 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Personalis Inc

$PSNL

Health Care · Life Sciences Tools & Services

IR Run Scenarios

$16.00

-0.37%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 260 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

Employees

260

Website

www.personalis.com/

IPO

2019-06-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)